These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33932781)

  • 41. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
    Jang YG; Go RE; Hwang KA; Choi KC
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular mechanism of Bisphenol A on androgen receptor antagonism.
    Huang X; Cang X; Liu J
    Toxicol In Vitro; 2019 Dec; 61():104621. PubMed ID: 31415812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
    Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Vorobiev AA; Kuznetsova IV; Shevkun NA; Koryakova AG; Karapetian RN; Trifelenkov AS; Kravchenko DV; Veselov MS; Chufarova NV
    Eur J Med Chem; 2015 Jun; 99():51-66. PubMed ID: 26046313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of persistent organic pollutants binding modes with androgen receptor ligand binding domain by docking and molecular dynamics.
    Xu XJ; Su JG; Bizzarri AR; Cannistraro S; Liu M; Zeng Y; Chen WZ; Wang CX
    BMC Struct Biol; 2013 Sep; 13():16. PubMed ID: 24053684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
    Song LN; Coghlan M; Gelmann EP
    Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
    J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of androgen receptor antagonists containing a pentafluorosulfanyl (SF
    Jin J; Zhou Y; Yang D; Zhang Q; Wang MW; Lu W
    Arch Pharm (Weinheim); 2018 Nov; 351(11):e1800175. PubMed ID: 30318752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.
    Hodgson MC; Astapova I; Cheng S; Lee LJ; Verhoeven MC; Choi E; Balk SP; Hollenberg AN
    J Biol Chem; 2005 Feb; 280(8):6511-9. PubMed ID: 15598662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD; Gleave ME
    Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.